In PURPOSE 1 (NCT04994509), data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Understand how drug use increases HIV risk and learn about prevention strategies that save lives. Medical experts explain ...

We need to ensure that new HIV infections are halted. Safo: Can you explain how aid flows? Because it’s not a question of, necessarily, the government provides the money and then it’s spent.

Image used for illustration. Picture: iStock. Human immunodeficiency virus (HIV) and sexually transmitted infections (STI) infections dropped in Gauteng between 2020 and 2024. The Gauteng ...

Persistence of stigma toward people living with HIV has puzzled scientists looking at the numerous destigmatization campaigns ...

Kidney Transplantation Among Those With HIV Infections Shown Safe and Effective, Study Suggests Oct. 17, 2024 — It is just as safe and effective for people with HIV in need of kidney ...

Last year, clinical trials showed that lenacapavir injections were 100% effective in preventing HIV infection among women in sub-Saharan Africa, who were HIV-negative. However, little information ...

One-shot’ approach that uses machine learning to screen immune cells could help to detect conditions with overlapping ...